Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
01-02 April, 2026
Not Confirmed
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Not Confirmed
Not Confirmed
07-09 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CGT Asia
Not Confirmed
Contact SupplierCGT Asia
Industry Trade Show
Not Confirmed
01-02 April, 2026
Industry Trade Show
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
07-09 April, 2026
Digital content
NEWS #PharmaBuzz
20 Dec 2022
// Nick Paul Taylor FIERCEPHARMA
https://www.fiercepharma.com/pharma/teetering-edge-midatech-plots-pivot-beyond-drug-delivery-platform-bioasis-buyout
13 Dec 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/12/13/2573101/0/en/Bioasis-Technologies-Inc-Announces-Merger-with-Midatech-Pharma-plc.html
13 Dec 2022
// ACCESSWIRE
https://www.accesswire.com/731666/Midatech-Pharma-PLC-Announces-Proposed-Acquisition-of-Bioasis-Technologies-Inc
14 Sep 2022
// NASDAQ
https://www.nasdaq.com/press-release/midatech-pharma-plc-announces-interim-results-for-the-six-months-to-30-june-2022-2022
21 Jun 2022
// ACCESSWIRE
https://www.accesswire.com/705853/Midatech-Pharma-PLC-Announces-MTX110-Development-for-the-Treatment-of-Glioma
14 Apr 2022
// ACCESSWIRE
https://www.accesswire.com/697474/Midatech-Pharma-PLC-Announces-Receipt-of-NASDAQ-Notice
Drugs in Development
Details:
Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (CNS) disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Recipient: Bioasis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination January 23, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Bioasis
Deal Size : Undisclosed
Deal Type : Termination
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
Details : Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous sys...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 23, 2023
Details:
Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (CNS) disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Recipient: Biodexa Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 13, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Biodexa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc
Details : Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous sys...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 13, 2022
Details:
MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour.
Lead Product(s): Panobinostat lactate,Lomustine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2022
Lead Product(s) : Panobinostat lactate,Lomustine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2022
Details:
The study has determined a proposed dose range for MTX110 for Phase II and has shown that repeated delivery of MTX110 via CED is feasible and safe.
Lead Product(s): Panobinostat lactate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 19, 2020
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Midatech Pharma PLC Announces Headline Results of MTX110 Phase I DIPG Study
Details : The study has determined a proposed dose range for MTX110 for Phase II and has shown that repeated delivery of MTX110 via CED is feasible and safe.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2020
Details:
The cash raised will be used to fund Midatech's MTX110 clinical programme, the development of an internal pipeline of Q-Sphera formulations for partnering, and for general corporate purposes.
Lead Product(s): Panobinostat lactate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: H.C. Wainwright & Co
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 18, 2020
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $3.0 million
Deal Type : Public Offering
Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million
Details : The cash raised will be used to fund Midatech's MTX110 clinical programme, the development of an internal pipeline of Q-Sphera formulations for partnering, and for general corporate purposes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 18, 2020
Details:
MTX110 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Medulloblastoma.
Lead Product(s): MTX110
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Recipient: University of Texas Health Science Center at Houston
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2020
Details : MTX110 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Medulloblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2020
Details:
MTX110 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Lead Product(s): MTX110,Gadolinium
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Luca Szalontay
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 11, 2020
Lead Product(s) : MTX110,Gadolinium
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Luca Szalontay
Deal Size : Inapplicable
Deal Type : Inapplicable
CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas
Details : MTX110 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 11, 2020
Details:
Panobinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Lead Product(s): Panobinostat lactate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Sabine Mueller, MD, PhD
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2018
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Sabine Mueller, MD, PhD
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Panobinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2018
Details:
Gelclair is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stomatitis.
Lead Product(s): Gelclair
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: PharPoint Research
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 06, 2018
Lead Product(s) : Gelclair
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : PharPoint Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gelclair is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stomatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
Share 
